Ascendis Pharma A/S (ASND) Scheduled to Post Quarterly Earnings on Thursday

Ascendis Pharma A/S (NASDAQ:ASND) will be issuing its quarterly earnings data on Thursday, April 25th.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its earnings results on Wednesday, February 7th. The biotechnology company reported ($1.66) EPS for the quarter, beating analysts’ consensus estimates of ($2.15) by $0.49. Ascendis Pharma A/S had a negative net margin of 180.61% and a negative return on equity of 16,574.15%. The firm had revenue of $148.62 million for the quarter, compared to analysts’ expectations of $97.02 million. On average, analysts expect Ascendis Pharma A/S to post $-4 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Ascendis Pharma A/S Trading Up 1.9 %

Shares of ASND stock opened at $144.83 on Wednesday. Ascendis Pharma A/S has a 12 month low of $66.03 and a 12 month high of $161.00. The stock has a market cap of $8.43 billion, a PE ratio of -15.66 and a beta of 0.50. The company’s fifty day moving average price is $149.15 and its 200-day moving average price is $125.48.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the company. Wedbush lifted their price target on Ascendis Pharma A/S from $207.00 to $225.00 and gave the stock an “outperform” rating in a research report on Thursday, February 8th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $173.00 price target on shares of Ascendis Pharma A/S in a research report on Thursday, April 18th. Wells Fargo & Company lifted their price target on Ascendis Pharma A/S from $196.00 to $260.00 and gave the stock an “overweight” rating in a research report on Friday, March 15th. Morgan Stanley reissued an “equal weight” rating and issued a $116.00 target price on shares of Ascendis Pharma A/S in a research report on Monday. Finally, JPMorgan Chase & Co. boosted their target price on Ascendis Pharma A/S from $165.00 to $167.00 and gave the stock an “overweight” rating in a research report on Tuesday, April 2nd. Two equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $173.25.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.